Previous 10 | Next 10 |
Tredegar Corporation (TG) is expected to report for quarter end 2023-12-31 Pharma-Bio Serv Inc (PBSV) is expected to report $0.02 for Q1 2024 Telos Corporation (TLS) is expected to report $-0.18 for Q4 2023 Coretec Group Inc (CRTG) is expected to report for quarter end 2023-12-31 ...
2024-03-13 18:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Genesco Inc. (GCO) is expected to report $2.66 for Q4 2024 Broadway Financial Corporation (BYFC) is expected to report for quarter end 2023-12-31 Oji Holdings Corporation ADR (OJIPY) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.54 for Q4 2024 GRI ...
Eurofins Scientific S.E. (ERFSF) is expected to report for Q4 2023 Biodesix Inc. (BDSX) is expected to report $-0.1 for Q4 2023 Tapinator Inc (TAPM) is expected to report for quarter end 2023-12-31 Rapid Micro Biosystems Inc. (RPID) is expected to report $-0.31 for Q4 2023 Galapag...
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Ch...
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present a...
2023-12-16 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KALA BIO Inc. (KALA) is expected to report $-2.15 for Q3 2023
2023-11-13 14:34:07 ET More on Kala Pharmaceuticals Seeking Alpha’s Quant Rating on Kala Pharmaceuticals Historical earnings data for Kala Pharmaceuticals Financial information for Kala Pharmaceuticals For further details see: Kala Pharmaceuticals ...
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM award, expected to fund operations into 2Q 2025 -- ...
News, Short Squeeze, Breakout and More Instantly...
Kala Pharmaceuticals Inc. Company Name:
KALA Stock Symbol:
NASDAQ Market:
Kala Pharmaceuticals Inc. Website:
2024-07-27 11:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is one of today's top gainers. The company's shares have moved 44.91% on the day to $6.55. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus pe...